Natriuretic and renoprotective effect of chronic oral neutral endopeptidase inhibition in acute renal failure

Figures & data

FIGURE 1.  Urinary excretion of protein (a) and nitrite (b) in control and ARF rats treated with or without candoxatril (30 mg/kg/day; orally, 3 weeks). n = 5 in each experimental group. Values are mean ± SEM. *p < 0.05 versus control.

FIGURE 2.  Urinary excretion of Na⁺ (a), creatinine (b), and plasma creatinine (c) values in control and ARF rats treated with or without candoxatril (30 mg/kg/day; orally, 3 weeks). Values are mean ± SEM. *p < 0.05 versus control; **p < 0.05 versus ARF.

FIGURE 3.  Vascular responses to (a) AngII (2.5, 5, 10, and 25 ng), (b) ET-1 (5, 10, and 25 ng), and (c) U46619 (10, 50, and 100 ng), a TxA₂ mimetic, in isolated kidneys prepared from control (Control) or ARF rats with (ARF + Candox; Con + Candox) or without (ARF) candoxatril (30 mg/kg/day; orally, 3 weeks) treatment. Numbers in the parentheses are the number of animals in each group. Values are mean ± SEM. *p < 0.05 versus control; **p < 0.05 versus ARF.

FIGURE 4.  Plasma level of AngII (a), ET-1 (b), and urinary excretion of TxB₂ (c) in control (Control) and ARF rats treated with (ARF + Candox; Con + Candox) or without (ARF) candoxatril (30 mg/kg/day; orally, 3 weeks) (n = 5 rats per group). Values are mean ± SEM. *p < 0.05 versus control; **p < 0.05 versus ARF.